Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm Study Evaluating the Safety and Efficacy of DIT101 in Subjects With Relapsed or Refractory Hematologic Malignancies

NCT07485504 is registered in ClinicalTrials.gov with Tcelltech Inc. as lead sponsor.

NCT NCT07485504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07485504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm Study Evaluating the Safety and Efficacy of DIT101 in Subjects With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Tcelltech Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 15, 2026
Completion date
October 15, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory hematologic malignancies